Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00581945 | Completed Phase 1 Results

• 1 other identifier: CACZ885B2204
• Study Type: interventional
• Target: 147
• Locations: 1 country
• Sites: 11

Brief Summary

Was to evaluate the safety, tolerability and efficacy of multiple doses of canakinumab (ACZ885) vs. placebo when administered via intravenous infusion (IV), on pulmonary function in patients with COPD

Conditions

Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (5)

• Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

  Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. FEV1 was measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation. All spirometry calibrations and evaluations followed the recommendations of the American Thoracic Society / European Respiratory Society guidelines for acceptability. A positive change from baseline in FEV1 indicates improvement in lung function.

  Baseline, Week 25 and Week 45

• Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted

  The FEV1 percent predicted expresses FEV1 as a percentage of the "predicted values" for participants of similar characteristics (height, age, sex, and sometimes race and weight). A positive change from baseline in FEV1 % predicted indicates improvement in lung function.

  Baseline, Week 25 and Week 45

• Change From Baseline in Forced Vital Capacity (FVC)

  Forced Vital Capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed by spirometry. A positive change from baseline in FVC indicates improvement in lung function.

  Baseline, Week 25 and Week 45

• Change From Baseline in Slow Vital Capacity (SVC)

  Vital Capacity is the amount of air that can be forcibly exhaled from the lungs after a full inhalation. Slow Vital Capacity (SVC) test is performed by having the patient slowly and completely blow out all of the air from their lungs. A positive change from baseline in SVC indicates improvement in lung function.

  Baseline, Week 25 and Week 45

• Change From Baseline in Forced Expiratory Flow 25% to 75%

  The forced expiratory flow (FEF) 25%-75% measurement describes the amount of air expelled from the lungs during the middle half (25% - 75%) of the forced vital capacity test and is measured using spirometry. A positive change from baseline in FEF indicates improvement in lung function.

  Baseline, Week 25 and Week 45

Secondary Outcomes (1)

• Number of Participants Who Experienced Serious Adverse Events or Discontinued Due to Adverse Events

  Adverse events were collected during the 45 week treatment period and the 12 week follow-up period.

Study Arms (2)

Canakinumab

EXPERIMENTAL

Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.

Drug: Canakinumab

Placebo

PLACEBO COMPARATOR

Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.

Drug: Placebo

Interventions

Canakinumab DRUG

The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.

Canakinumab

Placebo DRUG

Matching placebo to ACZ885 administered via intravenous infusion.

Placebo

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and/or female subjects from 40-80 years (inclusive) of age
• Subjects have a clinical diagnosis of COPD
• Smokers or Ex-smokers with a smoking history of at least 20 pack years
• Post-bronchodilator forced expiratory volume in 1 second (FEV1 ) at screening ≤ 50% of the predicted normal value
• Post-bronchodilator FEV1/FVC ratio \< 70%
• History of at least one treated exacerbation during the 24 months year prior to screening or C-Reactive Protein (CRP) ≥3.47 mg/L,
• Subjects should have no concomitant other lung disease or significant concomitant medical conditions that would affect the subjects' safety when participating in the study, or that would be expected to impact on the results of the study
• Female subjects must have been surgically sterilized at least 6 months prior to screening or must be using two forms of contraception, or postmenopausal women
• Able to provide written informed consent prior to study participation.
• Able to communicate well with the investigator and comply with the requirements of the study.

You may not qualify if:

• COPD exacerbation(s) requiring treatment within 4 weeks prior to first dosing
• History of lung reduction surgery
• Any undiagnosed nodule on chest x-ray
• Presence of certain medical conditions as specified by the protocol
• Subjects requiring oral or parenteral corticosteroids equivalent to \> 10 mg/day or \> 20 mg every other day of prednisone or prednisolone
• Documented homozygous alpha-1 antitrypsin deficiency.
• Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.
• Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
• A past medical history of clinically significant electrocardiogram (ECG) abnormalities or a family history of a prolonged QT-interval syndrome.
• A known hypersensitivity to drugs similar to the study drug.
• History of immunocompromise, including a positive HIV test result.
• A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
• History of drug or alcohol abuse within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during screening.

Sponsors & Collaborators

• Novartis: lead

Study Sites (11)

Novartis Investigator Site

Anaheim, California, 92801, United States

Location

Novartis Investigator Site

Los Angeles, California, 90095, United States

Location

Novartis Investigator Site

Panama City, Florida, 32405, United States

Location

Novartis Investigator Site

Marietta, Georgia, 300060, United States

Location

Novartis Investigator Site

Baltimore, Maryland, 21224, United States

Location

Novartis Investigator Site

Livonia, Michigan, 48152, United States

Location

Novartis Investigator Site

Minneapolis, Minnesota, 55402, United States

Location

Novartis Investigator Site

Omaha, Nebraska, 68198-5885, United States

Location

Novartis Investigator Site

Buffalo, New York, 14215, United States

Location

Novartis Investigator Site

Spartanburg, South Carolina, 29303, United States

Location

Novartis Investigator Site

Richmond, Virginia, 23225, United States

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

canakinumab

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Novartis Pharmaceuticals
• Organization: Study Director

862-778-8300

Study Officials

• NOVARTIS

  Novartis investigator site

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: December 21, 2007
• First Posted: December 28, 2007
• Study Start: January 1, 2007
• Primary Completion: May 1, 2010
• Study Completion: May 1, 2010
• Last Updated: June 30, 2011
• Results First Posted: June 27, 2011

Record last verified: 2011-06

Locations

US (11)